Scarica l'app Stockscreener
84.82
2.31%
1.69
Precedente Chiudi:
$83.13
Aprire:
$83.14
Volume 24 ore:
1.65M
Relative Volume:
0.91
Capitalizzazione di mercato:
$5.10B
Reddito:
-
Utile/perdita netta:
$-116.25M
Rapporto P/E:
-35.47
EPS:
-2.3912
Flusso di cassa netto:
$-91.19M
1 W Prestazione:
-10.63%
1M Prestazione:
+41.42%
6M Prestazione:
+205.83%
1 anno Prestazione:
+539.95%
Intervallo 1D:
$82.53
$89.85
Intervallo di 1 settimana:
$82.22
$96.14
Portata 52W:
$12.84
$97.78
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Nome
Oruka Therapeutics Inc
Settore
Industria
Telefono
650-606-7910
Indirizzo
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
84.59 | 5.01B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.94 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.97 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Piper Sandler | Overweight |
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-10-27 | Iniziato | Guggenheim | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-10-11 | Iniziato | Stifel | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | Leerink Partners | Outperform |
| 2024-09-16 | Iniziato | TD Cowen | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2018-02-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Iniziato | Dawson James | Buy |
Mostra tutto
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Oruka Therapeutics (ORKA) Sees 8.1% Decline - GuruFocus
Oruka Therapeutics Insider Sold Shares Worth $472,079, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares - Benzinga
Form 13D/A ORUKA THERAPEUTICS For: 1 July By Investing.com - Investing.com India
Fairmount Healthcare Fund II sells $300m Oruka Therapeutics stock By Investing.com - Investing.com Australia
Form 144 | Oruka Therapeutics(ORKA.US) Insider Proposes to Sell 300.01 Million in Common Stocks - Moomoo
Insider Sell: Laura Sandler Sells 5,000 Shares of Oruka Therapeu - GuruFocus
Form 144 Oruka Therapeutics For: 1 July By Investing.com - Investing.com Nigeria
Fairmount Healthcare Fund II sells $300m Oruka Therapeutics stock - Investing.com
Form 144 Oruka Therapeutics For: 1 July - Investing.com UK
Why Oruka Therapeutics (ORKA) Is Up 13.6% After Russell Index Reclassification Into Growth Benchmarks - simplywall.st
Oruka Therapeutics COO Laura Sandler sells $472,078 in stock - Investing.com
Oruka Therapeutics COO Laura Sandler sells $472,078 in stock By Investing.com - Investing.com South Africa
Form 4 Oruka Therapeutics Inc For: 1 July By Investing.com - Investing.com India
Form 4 Oruka Therapeutics Inc For: 1 July - Investing.com UK
Price to book forward of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News - Insider Monkey
Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says - marketscreener.com
UBS raises Oruka Therapeutics stock price target to $130 on efficacy data outlook - Investing.com Australia
Price to book forward of Oruka Therapeutics, Inc. – XETR:HQ1 - TradingView
Top 10 Hot Stocks with the Highest Upside Potential - Insider Monkey
Oruka Therapeutics stock hits 52-week high at 91.2 USD By Investing.com - Investing.com Australia
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) dropped from Russell 3000E Index - marketscreener.com
Oruka Therapeutics stock hits 52-week high at 91.2 USD - Investing.com
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) added to Russell 2000 Growth Benchmark - marketscreener.com
Oruka Therapeutics, Inc.(NasdaqGM:ORKA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) added to Russell 3000E Growth Benchmark - marketscreener.com
Stifel Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $150 - Moomoo
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) dropped from Russell Microcap Index - marketscreener.com
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) dropped from Russell 2500 Value Benchmark - marketscreener.com
Oruka Therapeutics, Inc.(NasdaqGM:ORKA) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
Enterprise value to EBITDA forward of Oruka Therapeutics, Inc. – TRADEGATE:HQ1 - TradingView
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) added to Russell 3000 Growth Benchmark - marketscreener.com
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean - Yahoo Finance
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean - The Motley Fool
Oruka Therapeutics, Inc. Actuals & Estimates (DUS:HQ1) - TradingView
Enterprise value to revenue forward of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
Price to earnings forward of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
ORKA Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
HQ1 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Oruka Therapeutics, Inc. – TRADEGATE:HQ1 - TradingView
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors? - AOL.com
Price to book forward of Oruka Therapeutics, Inc. – TRADEGATE:HQ1 - TradingView
Price to sales forward of Oruka Therapeutics, Inc. – TRADEGATE:HQ1 - TradingView
Oruka Therapeutics, Inc. (NASDAQ: ORKA) Share Price, ORKA Stock News, ORKA Share Price & Updates - Kalkine
Oruka Therapeutics (ORKA) Is Up 5.1% After Positive Trial Update And Insider Share SalesWhat's Changed - Sahm
Oruka Therapeutics Inc Azioni (ORKA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oruka Therapeutics Inc Azioni (ORKA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Jul 01 '26 |
Sale |
84.43 |
3,553,410 |
300,014,406 |
1,131,954 |
| Sandler Laura Lee | Chief Operating Officer |
Jul 01 '26 |
Option Exercise |
7.80 |
5,000 |
39,000 |
241,384 |
| Sandler Laura Lee | Chief Operating Officer |
Jul 01 '26 |
Sale |
94.42 |
5,000 |
472,079 |
236,384 |
| Agarwal Arjun | Senior Vice President, Finance |
Jun 22 '26 |
Sale |
80.95 |
1,587 |
128,468 |
15,312 |
| Agarwal Arjun | Senior Vice President, Finance |
Jun 12 '26 |
Option Exercise |
15.88 |
9,459 |
150,175 |
26,753 |
| Agarwal Arjun | Senior Vice President, Finance |
Jun 12 '26 |
Sale |
69.72 |
9,459 |
659,508 |
17,294 |
| Agarwal Arjun | Senior Vice President, Finance |
Jun 15 '26 |
Sale |
69.69 |
395 |
27,528 |
16,899 |
| Goncalves Joana | Chief Medical Officer |
Jun 15 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
40,665 |
| Goncalves Joana | Chief Medical Officer |
Jun 15 '26 |
Sale |
69.28 |
7,947 |
550,607 |
32,718 |
| Klein Lawrence Otto | Chief Executive Officer |
Jun 15 '26 |
Sale |
69.69 |
1,729 |
120,494 |
925,580 |
1.21%
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):